Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.
Last trade$0.7856
Day change-$0.0709 (-8.28%)
Day range$0.757 – $0.864
Volume232,662
Market cap$26M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$25.7M
Price / earnings
—
Price / book
0.45×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.55×
Profitability
Earnings per share
-$1.72
Return on assets
-88.16%
Return on equity
-90.82%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.64×
Quick ratio
3.64×
Cash ratio
2.51×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.79M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LITS, quarterly periods
Line item
Q1 FY2027 Sep 30, 2026
Q4 FY2026 Jun 30, 2026
Q3 FY2026 Mar 31, 2026
Q2 FY2026 Dec 31, 2025
Q1 FY2026 Sep 30, 2025
Revenue
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
Selling, general and administrative
$2.36M
$2.91M
$2.74M
$3.31M
$3.1M
Research and development
$22K
$36K
$30K
$46K
$10K
Total operating expenses
$2.38M
$11.36M
$21.61M
$3.35M
$3.11M
Operating income
-$2.38M
-$11.36M
-$21.61M
-$3.35M
-$3.11M
Interest expense
$0
$0
$0
$0
$0
Income before taxes
$16.02M
-$13.02M
-$23.69M
-$30.8M
-$3.64M
Income taxes
$0
$0
$0
$0
$0
Net income
$16.02M
-$13.02M
-$23.69M
-$30.8M
-$3.64M
Net income attributable to common shareholders
$16.02M
-$13.02M
-$23.69M
-$30.8M
-$3.64M
EBITDA
-$2.38M
-$11.36M
-$21.61M
-$3.35M
-$3.11M
Basic earnings per share
$0.48
-$0.36
-$0.66
-$0.82
-$0.12
Diluted earnings per share
$0.48
-$0.36
-$0.66
-$0.82
-$0.12
Recent news
Company coverage with links to the original publishers.
Lite Strategy, Inc. (NASDAQ: LITS), the first U.S. public company to adopt Litecoin as its primary treasury reserve asset, will participate in a featured panel at the Litecoin Foundation Summit on June 22-23, 2026 in Amsterdam. The panel will discuss Litecoin's institutional evolution, featuring CEO Jay File and board members including Litecoin creator Charlie Lee. This marks the first time a NASDAQ-listed digital asset treasury company has appeared at the annual summit.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.